TRSBF 3SBio Inc. — dividend yield, history & ex-dividend dates
3SBio Inc. is a China-based investment holding company deeply engaged in the biopharmaceutical sector, encompassing the entire value chain from research and development to manufacturing, marketing, and sales of its innovative products. The company's extensive biopharmaceutical portfolio caters to a wide array of therapeutic needs. This includes treatments for various blood disorders like TPIAO (for chemotherapy-induced or immune thrombocytopenia), EPIAO and SEPO (recombinant erythropoietins for anemia), and SPARIN (a low-molecular-weight heparin for deep vein thrombosis prophylaxis and treatment, as well as for preventing clotting during hemodialysis), alongside Aiyishu for iron-deficiency anemia. Its autoimmune and inflammatory disease offerings feature YISAIPU, a tumor necrosis factor inhibitor effective against rheumatoid arthritis, ankylosing spondylitis, and psoriasis. In the oncology domain, 3SBio provides Cipterbin for HER2-positive metastatic breast cancer (in combination with chemotherapy), Intefen (a recombinant human interferon for lymphatic/hematopoietic malignancies and viral infections), and Inleusin (human interleukin-2 for renal cell carcinoma, melanoma, and thoracic fluid accumulation). Other specialized products address conditions such as male alopecia and alopecia areata (Mandi), acute rejection post-renal transplant (Xenopax), glycemic control in type 2 diabetes (Byetta), and diabetic retinopathy (Qiming Keli). In addition to its pharmaceutical operations, 3SBio diversifies its activities through services encompassing trading, project management, consulting, technology, and agriculture. The company has forged strategic collaboration agreements with a multitude of international partners, including prominent names like AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and the Dana-Farber Cancer Institute. Established in 1993, the company maintains its headquarters in Shenyang, China.
Dividend Snapshot
Key Metrics
Current Yield
1.48%
The annual dividend as a percentage of the share price. A 3% yield is about $3 of dividends a year for every $100 invested at today's price.Annualized Dividend
$0.0319
The most recent payment scaled to a full year by how often it's paid. A $0.25 quarterly dividend annualizes to $1.00.Frequency
A Annual
How often the dividend is paid: Q = quarterly (4x a year), M = monthly, S = semi-annual, A = annual.Rank Score
49.9
Our 0-100 house score blending yield, payout safety, growth and momentum. Higher means a stronger profile on those factors in our model — a research score, not advice or a recommendation to buy.RSI (14)
26
Relative Strength Index (0-100), a price-momentum gauge. Above 70 is often called 'overbought', below 30 'oversold'. A technical signal, not a dividend metric.52-Week Range
$2.00 – $4.41
The lowest and highest price over the past year — shows where today's price sits in its recent range.Payout Ratio
6.77%
The share of GAAP earnings paid out as dividends. Lower leaves more cushion; above 100% means paying out more than the company earns. It shows n/a for BDCs, REITs and funds, which pay out of cash flow / net investment income rather than GAAP earnings, so this ratio doesn't apply.Years Paying
8
How many years of payments we have on record. This can understate very long histories where our data doesn't reach far enough back.Price / Book
2.21
Price-to-book ratio: share price divided by book value per share. A rough valuation gauge, most useful for asset-heavy sectors like REITs, banks and insurers.S.A.F.E. Dividend Read
Quote & Key Data
Dividend Growth
Why the Yield Moved (90 Days)
TRSBF's dividend yield rose from 1.45% to 1.48% over the past ~90 days (+0.04 pp). Of that move, +0.00 pp came from changes in the dividend rate and +0.03 pp from the share price ($2.20 → $2.15). A yield that rises because the price fell is not an improvement in the payout itself.
Yield vs Its Own History
Across 332 daily observations over the past 16 months, TRSBF's current yield is higher than approximately 87% of them. Our stored price history for TRSBF covers the past 16 months; 3- and 5-year averages are not yet computable from it and are deliberately not shown.
Adjusted Price History
Dividend History
Dividend Payment History
Ex-dividend calendar →| Amount | Type | Declared | Ex-Date | Record | Pay |
|---|---|---|---|---|---|
| $0.0319 A | Regular | - | Jul 21, 2026 | Jul 23, 2026 | Aug 04, 2026 |
| $0.0318 A | Regular | - | Jul 21, 2025 | Jul 23, 2025 | Aug 15, 2025 |
| $0.0320 A | Regular | - | Jul 22, 2024 | Jul 23, 2024 | Aug 05, 2024 |
| $0.0128 A | Regular | - | Jun 27, 2023 | Jun 28, 2023 | Jul 11, 2023 |
| $0.0255 A | Regular | - | Jun 27, 2022 | Jun 28, 2022 | Jul 11, 2022 |
| $0.0087 A | Regular | - | Jun 29, 2018 | Jul 03, 2018 | Jul 30, 2018 |
Peer Comparison
Selected Biotechnology dividend payers we cover, strongest DividendRank first — for context, not a recommendation.
| Ticker | Name | Yield | 5-Yr Growth | Streak | Rank |
|---|---|---|---|---|---|
| XOMAO | XOMA Corporation | 8.38% | - | 0 yrs | 44 |
| XOMAP | XOMA Corporation | 8.63% | - | 0 yrs | 44 |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.48% | - | 0 yrs | 42 |
| TECH | Bio-Techne Corporation | 0.44% | 0.0% | 0 yrs | 42 |
Related Guides & Lists
TRSBF dividend — frequently asked questions
Does 3SBio Inc. pay a dividend?
Yes. 3SBio Inc. (TRSBF) currently pays a dividend. The annualized dividend is about $0.03 per share, a yield of approximately 1.48%.
What is 3SBio Inc.'s dividend yield?
3SBio Inc.'s dividend yield is approximately 1.48%, based on the most recent regular payment annualized against the current share price. Yields move as the share price changes.
How often does 3SBio Inc. pay dividends?
3SBio Inc. pays dividends annually — 1 time per year.
How long has 3SBio Inc. paid dividends?
3SBio Inc. has 8 years of dividend payments on record.
Data updated Sep 13, 2026. This research page is generated from Dividendly's structured market and dividend dataset using the approach described on our methodology and data sources pages. Data is automatically validated using defined rules and may also be periodically reviewed. Research only, not investment advice. Spotted a data error? Report it.